Delivery Order SPE2DB22D3501-SPE2DB26FTG70
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,852.74 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes, with an ultimate completion date of September 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $14,887.74 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Prolia 60 mg/ml syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 20, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $26,034.19 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes under a firm fixed-price contract. The delivery order, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a competitively awarded non-set-aside procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $32,625.43 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, non-set-aside contract executed on August 19, 2025, with performance to take place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $43,702.03 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/mL syringes. This competitively awarded, firm fixed-price contract with an ultimate completion date of November 4, 2025, represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order carries no set-aside designation, reflecting the contractor's competitive qualification to meet...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $26,886.29 by the Defense Logistics Agency (DLA) on October 23, 2025, with an ultimate completion date of October 24, 2025. The order is for Prolia 60 mg/ml syringes and represents a firm fixed price, competitively awarded contract with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,746.68 for Prolia 60 mg/ml syringes on June 25, 2025, with an ultimate completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $7,575.13 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Prolia 60 mg/ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The delivery is scheduled for completion by October 23, 2025, with performance taking place at...
- The Defense Logistics Agency awarded a delivery order valued at $29,291.77 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation, indicating open...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,271.66 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes. This competitive award, with no set-aside designation, was executed on October 30, 2025, with an ultimate completion date of October 31, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTG70Delivery Order
The Defense Logistics Agency (DLA) awarded a $24,876.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This non-competitive award, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's headquarters and primary distribution center for federal medical procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, holds a significant prime IDC valued at $999,999,999.00 through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and programs worldwide. This delivery order for Prolia, a bone health medication used in the treatment of osteoporosis, exemplifies the company's role in fulfilling federal medical supply requirements across multiple therapeutic domains through its established relationship with DLA's Medical Supply Chain. The non-set-aside designation and firm fixed pricing structure are consistent with AmerisourceBergen's established pattern of competitively awarded federal contracts for both specialty and generic medications supporting Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.9k | 10/28/25 |